WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407833
CAS#: 2225902-88-3
Description: CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
MedKoo Cat#: 407833
Name: CMP3a
CAS#: 2225902-88-3
Chemical Formula: C28H27F3N6O2S
Exact Mass: 568.1868
Molecular Weight: 568.6192
Elemental Analysis: C, 59.14; H, 4.79; F, 10.02; N, 14.78; O, 5.63; S, 5.64
Synonym: CMP3a; CMP-3a; CMP 3a.
IUPAC/Chemical Name: (R)-5-{7-[1-(2-Dimethylamino-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}-3-[1-(2-trifluoromethyl-phenyl)-ethoxy]-thiophene-2-carboxamide
InChi Key: BQODGOMHYSMCGK-QGZVFWFLSA-N
InChi Code: InChI=1S/C28H27F3N6O2S/c1-17(20-6-4-5-7-21(20)28(29,30)31)39-23-13-24(40-26(23)27(32)38)22-15-33-25-12-18(8-9-37(22)25)19-14-34-36(16-19)11-10-35(2)3/h4-9,12-17H,10-11H2,1-3H3,(H2,32,38)/t17-/m1/s1
SMILES Code: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(C3=CN=C4C=C(C5=CN(CCN(C)C)N=C5)C=CN43)S1)N
Appearance: Yellow solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 568.6192 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A,
Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum
HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and
radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest.
2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24. PubMed
PMID: 28737508; PubMed Central PMCID: PMC5531394.
NEK2 was among the most differentially expressed kinase-encoding genes in GSC-containing cultures (glioma spheres), and it was required for in vitro clonogenicity, in vivo tumor propagation, and radioresistance. Mechanistically, the formation of a protein complex comprising NEK2 and EZH2 in glioma spheres phosphorylated and then protected EZH2 from ubiquitination-dependent protein degradation in a NEK2 kinase activity-dependent manner. Clinically, NEK2 expression in patients with glioma was closely associated with EZH2 expression and correlated with a poor prognosis. NEK2 expression was also substantially elevated in recurrent tumors after therapeutic failure compared with primary untreated tumors in matched GBM patients.
